Document is current
Any future updates will be listed below
-
Authors
Williamson, Nicola https://orcid.org/0009-0003-1873-5312
Morel, Thomas https://orcid.org/0000-0002-0690-5359
Bradley, Helena https://orcid.org/0000-0002-7077-2183
Lydon, Aoife
Clifford, Molly https://orcid.org/0000-0002-9707-465X
Cronin, Patrick https://orcid.org/0009-0005-8881-1856
Biagioni, Milton https://orcid.org/0000-0003-1985-8923
-
Funding
Funding for this research was provided by:
UCB
- License Information
-
More Information
Article History
Received: 14 February 2025
Accepted: 3 April 2025
First Online: 13 May 2025
Declarations
:
: Nicola Williamson, Thomas Morel, and Milton Biagioni are employees and shareholders of UCB Pharma. Aoife Lydon, Molly Clifford, and Helena Bradley are employees of Adelphi Values Ltd, a health outcomes agency who were paid by UCB Pharma for the conduct of this research. Patrick Cronin was an employee of Adelphi Values Ltd at the time of this research.
: Ethical approval and oversight was provided by WCG IRB (tracking number: 20223101). Approval notices were received in June 2022. This study was designed and conducted in line with principles outlined in the Declaration of Helsinki and Good Clinical Practice guidelines. All PwP and clinicians provided written informed consent prior to commencement of study-related activities.
